Thinking about CNS Metastasis in Cutaneous Lymphoma: Analysis of Existing Data
Publication date: Available online 16 October 2017 Source:Leukemia Research Reports Author(s): Yi Yang, Heather Wickless To determine some of the key clinical features that help prompt clinicians to pursue additional work-up for evaluation of CNS involvement of MF, we conducted a systematic review to better define characteristics, treatments, outcomes, and mortality in these patients. Our analyses indicated that neurologic surveillance after the diagnosis of MF is crucial. Review of systems should include change in mentation, vestibular, and ocular symptoms. Progression to CNS involvement does not always occur in tande...
Source: Leukemia Research Reports - October 17, 2017 Category: Hematology Source Type: research
Diagnostic and Therapeutic Implications of Genetic Heterogeneity in Myeloid Neoplasms Uncovered by Comprehensive Mutational Analysis
Publication date: Available online 20 September 2017 Source:Leukemia Research Reports Author(s): Sarah M. Choi, Ben Goldenson, Lo Ann Peterson, Shira Dinner, Brady L. Stein, Amir Behdad While growing use of comprehensive mutational analysis has led to the discovery of innumerable genetic alterations associated with various myeloid neoplasms, the under-recognized phenomenon of genetic heterogeneity within such neoplasms creates a potential for diagnostic confusion. Here, we describe two cases where expanded mutational testing led to amendment of an initial diagnosis of chronic myelogenous leukemia with subsequent al...
Source: Leukemia Research Reports - September 21, 2017 Category: Hematology Source Type: research
An unusual type of myeloid sarcoma localization following myelofibrosis: a case report and literature review
We report the case of a patient with MS following myelofibrosis with multiple subcutaneous, cutaneous and muscle localizations; the latter has been reported in the literature as anecdotal. In this way we aimed to enhance the understanding of this disease. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - July 28, 2017 Category: Hematology Source Type: research
Successful Salvage Chemotherapy and Allogeneic Transplantation of an Acute Myeloid Leukemia Patient with Disseminated Fusarium solani Infection
We report a case of disseminated Fusarium in a patient with relapsed AML who underwent successful chemotherapy and haplo-identical allogeneic SCT with administration of granulocyte colony stimulating factor (G-CSF) and granulocyte infusions. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - July 19, 2017 Category: Hematology Source Type: research
EB virus reactivation triggers thrombotic thrombocytopenic purpura in a healthy adult
Publication date: Available online 20 June 2017 Source:Leukemia Research Reports Author(s): Satoko Oka, Masaharu Nohgawa Thrombotic thrombocytopenic purpura (TTP) is rare but life-threatening disease, characterized typically by microangiopathic hemolytic anemia (MAHA), profound peripheral thrombocytopenia and severe deficiency in the von Willebrand factor-cleaving prortease ADAMTS13. It has been reported that acquired immune TTP is closely associated with human immunodeficiency virus infection and influenza infection or vaccination. However, it has not been reported to be associated with Epstein Barr Virus infection or...
Source: Leukemia Research Reports - June 21, 2017 Category: Hematology Source Type: research
Cellular Immune Profiling after Sequential Clofarabine and Lenalidomide for High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
We report preliminary cellular immune profiling of four cases receiving sequential clofarabine and lenalidomide for high risk MDS and AML in a phase I study. Our results highlight the potential of immune profiling for monitoring immune-modifying agents in high risk MDS and AML. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - April 14, 2017 Category: Hematology Source Type: research
Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia
We report the outcomes of six older adults at high risk of anthracycline-induced cardiotoxicity who received dexrazoxane during induction/re-induction therapy. Five had preserved left-ventricular function while two proceeded onto stem-cell transplantation. Additional investigation of dexrazoxane in adult leukemia therapy is warranted, particularly in older patients at highest risk for cardiovascular mortality. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - April 14, 2017 Category: Hematology Source Type: research
Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia
Publication date: Available online 12 April 2017 Source:Leukemia Research Reports Author(s): Seiichiro Katagiri, Tetsuzo Tauchi, Keiko Ando, Seiichi Okabe, Moritaka Gotoh, Kazuma Ohyashiki It is difficult to predict musculoskeletal pain as a withdrawal syndrome following the discontinuation of imatinib (IM) in patients with chronic myeloid leukemia. We investigated a link between physical size and musculoskeletal pain following IM discontinuation. In total, seven out of 24 patients developed musculoskeletal pain after discontinuing IM. Those with symptoms had a significantly lower body weight (BW) and body mass ind...
Source: Leukemia Research Reports - April 13, 2017 Category: Hematology Source Type: research
On Arsenic Trioxide in the Clinical Treatment of Acute Promyelocytic Leukemia
Publication date: Available online 9 March 2017 Source:Leukemia Research Reports Author(s): Peng Zhang Arsenic is generally considered hypertoxic. However,it has been used in traditional Chinese medicine since ancient times, to treat serious illnesses. Recently, a single dose of arsenic trioxide (As2O3) has been found especially effective in treating acute promyelocytic leukemia (APL). Generally speaking, As2O3 is a more effective treatment of APL than other, newer medications and has less severe adverse reactions and greater safety. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - March 9, 2017 Category: Hematology Source Type: research
Aspirin and Risk of Multiple Myeloma in Adults: A Systematic Review and Meta-Analysis
Publication date: Available online 28 February 2017 Source:Leukemia Research Reports Author(s): Shing Fung Lee, Ting Ying Ng, Frank Chi Sing Wong, Stewart Yuk Tung Multiple myeloma is a relatively uncommon plasma cell malignancy. Preclinical and clinical studies have suggested that aspirin might modify the risk of multiple myeloma. We performed a systematic review and meta-analysis of studies to examine the association between regular aspirin use and risk of multiple myeloma. Five observational studies including 332,660 adults were evaluated. The pooled estimate had a hazard ratio of 0.90 (95% confidence interval = 0...
Source: Leukemia Research Reports - February 28, 2017 Category: Hematology Source Type: research
Clofarabine Desensitization: A Case Report
We describe a relapsed AML patient who had two prior severe reactions to clofarabine involving rigors, emesis, tachycardia, hypotension, and acute kidney injury. Given previous prolonged remission achieved with clofarabine and cytarabine therapy years prior, rechallenge was undertaken upon discovery of AML relapse. We designed a desensitization protocol performed with the first dose of clofarabine, leading to successful administration of the entire clofarabine/cytarabine treatment course. From this case we show promise for clofarabine rechallenge after prior hypersensitivity reactions in patients with few treatment options...
Source: Leukemia Research Reports - February 12, 2017 Category: Hematology Source Type: research
A case of acute myeloid leukemia with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic leukemia
We report a chronic myelomonocytic leukemia (CMML) patient, initially Ph chromosome negative at presentation, with rapid disease progression to AML and appearance of Ph chromosome and BCR-ABL e6a2, a very uncommon fusion transcript. The patient died of the subsequent emergence and dominance of a Ph negative leukemic clone. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - January 30, 2017 Category: Hematology Source Type: research
A Rare Breed: Wild-Type BRAF and IgHV Expression in a 29 Year Old Lady with Classical Hairy Cell Leukemia
Publication date: Available online 24 January 2017 Source:Leukemia Research Reports Author(s): Aneesha Hossain, Hind Rafei, Amar Jariwala, Khaled El-Shami The V600 BRAF mutation has been described as a key mutation in the pathogenesis of classical hairy cell leukemia (c-HCL) cases without expression of a mutant immunoglobulin heavy chain (IgHV). Here we present a rare case of c-HCL with neither V600 BRAF mutation nor the aforementioned IgHV variant successfully treated with cladribine and review the current literature on its use in women of childbearing age/pregnancy. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - January 23, 2017 Category: Hematology Source Type: research
“Hemophagocytic Lymphohistiocytosis after EBV reactivation and Ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia”
We report the clinical course of a patient with relapsed CLL who developed acute symptoms soon after starting ibrutinib. Hyperpyrexia, splenomegaly, hyperferritinemia, hypertriglyceridemia, cytopenias, and a typical cytokine pattern, i.e. high interleukin (IL)− 6, IL10 and IL18, were consistent with a diagnosis of HLH. Coexistent Epstein Barr virus reactivation was documented. Ibrutinib-induced impairment of NK degranulation, associated with EBV reactivation and CLL-related immunodeficiency may have contributed to the development of HLH in our patient. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - January 22, 2017 Category: Hematology Source Type: research
Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study
Publication date: 2017 Source:Leukemia Research Reports, Volume 7 Author(s): António Almeida, Ana Rita Ferreira, Maria João Costa, Sofia Silva, Khalil Alnajjar, Isabel Bogalho, Francesca Pierdomenico, Susana Esteves, Mafalda Alpoim, Gil Braz, Emilia Cortesão, Ricardo Pinto Retrospective data was collected from 77 elderly acute myeloid leukemia (AML) patients treated with Azacitidine (AZA) and 50 elderly AML patients treated with intensive chemotherapy (IC) from 4 Portuguese Hospitals. Median OS was 10.6 months in those receiving AZA as 1st line. Response (overall response rate 44%) had a significant impact...
Source: Leukemia Research Reports - December 28, 2016 Category: Hematology Source Type: research
